Revolutionizing drug discovery with a best-in-class computational drug discovery platform, which integrates AI, machine learning, generative therapeutic design, and physics-based approaches (e.g., quantum chemistry, statistical mechanics, molecular dynamics, free energy methods) to improve and accelerate the design of the next generation of drugs over multiple therapeutic areas. Currently focused on small-molecule therapeutics for a variety of targets in the DNA damage response (DDR) pathways and immuno-oncology. In particular, Denovicon is progressing first-in-class molecules that selectively target PARP1 and PARP2 for various diseases in oncology, immunology, neuroscience, and cardiovascular, as well as PARP7 for multiple oncology indications.